Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply

A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc.

Detalles Bibliográficos
Autores principales: Roberts, Ian, Shakur, Haleema
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797008/
http://dx.doi.org/10.1186/1745-6215-10-111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797008/
http://dx.doi.org/10.1186/1745-6215-10-111

Ejemplares similares